Cargando…
Autologous Fat Grafting in the Treatment of Facial Scleroderma
Systemic sclerosis (SSc) is a rare systemic autoimmune disease, characterized by progressive cutaneous and internal organ fibrosis. Orofacial manifestations of systemic sclerosis are extremely disabling and treatment options are limited. In this study, we aimed to assess the safety and efficacy of a...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6093005/ https://www.ncbi.nlm.nih.gov/pubmed/30154838 http://dx.doi.org/10.1155/2018/6568016 |
_version_ | 1783347629376143360 |
---|---|
author | Gheisari, Mehdi Ahmadzadeh, Arman Nobari, Nilofar Iranmanesh, Behzad Mozafari, Nikoo |
author_facet | Gheisari, Mehdi Ahmadzadeh, Arman Nobari, Nilofar Iranmanesh, Behzad Mozafari, Nikoo |
author_sort | Gheisari, Mehdi |
collection | PubMed |
description | Systemic sclerosis (SSc) is a rare systemic autoimmune disease, characterized by progressive cutaneous and internal organ fibrosis. Orofacial manifestations of systemic sclerosis are extremely disabling and treatment options are limited. In this study, we aimed to assess the safety and efficacy of autologous fat grafting in the face of patients with systemic sclerosis. We enrolled 16 SSc patients suffering from facial sclerosis and limited mouth opening capacity. Autologous fat injection ranging from 15 to 40 ml was administered per patient, based on their face morphology. The patients were evaluated at baseline and 3 months after fat injection. Evaluations included mouth opening capacity, mouth handicap in systemic sclerosis (MHISS), Rodnan skin sclerosis score, skin biophysical properties using a sensitive biometrologic device with the assessment of cutaneous resonance running time (CRRT), volumizing and aesthetic effects based on pre- and posttreatment photographs, possible side effects, and global patient satisfaction. Clinical assessment showed autologous fat transfer significantly improved mouth opening capacity and the MHISS and Rodnan score of patients with facial scleroderma (p value <.001). The aesthetic and/or functional results of fat injection were satisfying to about 80% of the patients. The changes in CRRT values were not significant. Our findings support the possible therapeutic role of autologous fat grafting in improving facial scleroderma both in aesthetic and in functional aspects. This trial is registered with IRCT20180209038677N1. |
format | Online Article Text |
id | pubmed-6093005 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-60930052018-08-28 Autologous Fat Grafting in the Treatment of Facial Scleroderma Gheisari, Mehdi Ahmadzadeh, Arman Nobari, Nilofar Iranmanesh, Behzad Mozafari, Nikoo Dermatol Res Pract Clinical Study Systemic sclerosis (SSc) is a rare systemic autoimmune disease, characterized by progressive cutaneous and internal organ fibrosis. Orofacial manifestations of systemic sclerosis are extremely disabling and treatment options are limited. In this study, we aimed to assess the safety and efficacy of autologous fat grafting in the face of patients with systemic sclerosis. We enrolled 16 SSc patients suffering from facial sclerosis and limited mouth opening capacity. Autologous fat injection ranging from 15 to 40 ml was administered per patient, based on their face morphology. The patients were evaluated at baseline and 3 months after fat injection. Evaluations included mouth opening capacity, mouth handicap in systemic sclerosis (MHISS), Rodnan skin sclerosis score, skin biophysical properties using a sensitive biometrologic device with the assessment of cutaneous resonance running time (CRRT), volumizing and aesthetic effects based on pre- and posttreatment photographs, possible side effects, and global patient satisfaction. Clinical assessment showed autologous fat transfer significantly improved mouth opening capacity and the MHISS and Rodnan score of patients with facial scleroderma (p value <.001). The aesthetic and/or functional results of fat injection were satisfying to about 80% of the patients. The changes in CRRT values were not significant. Our findings support the possible therapeutic role of autologous fat grafting in improving facial scleroderma both in aesthetic and in functional aspects. This trial is registered with IRCT20180209038677N1. Hindawi 2018-08-01 /pmc/articles/PMC6093005/ /pubmed/30154838 http://dx.doi.org/10.1155/2018/6568016 Text en Copyright © 2018 Mehdi Gheisari et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Gheisari, Mehdi Ahmadzadeh, Arman Nobari, Nilofar Iranmanesh, Behzad Mozafari, Nikoo Autologous Fat Grafting in the Treatment of Facial Scleroderma |
title | Autologous Fat Grafting in the Treatment of Facial Scleroderma |
title_full | Autologous Fat Grafting in the Treatment of Facial Scleroderma |
title_fullStr | Autologous Fat Grafting in the Treatment of Facial Scleroderma |
title_full_unstemmed | Autologous Fat Grafting in the Treatment of Facial Scleroderma |
title_short | Autologous Fat Grafting in the Treatment of Facial Scleroderma |
title_sort | autologous fat grafting in the treatment of facial scleroderma |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6093005/ https://www.ncbi.nlm.nih.gov/pubmed/30154838 http://dx.doi.org/10.1155/2018/6568016 |
work_keys_str_mv | AT gheisarimehdi autologousfatgraftinginthetreatmentoffacialscleroderma AT ahmadzadeharman autologousfatgraftinginthetreatmentoffacialscleroderma AT nobarinilofar autologousfatgraftinginthetreatmentoffacialscleroderma AT iranmaneshbehzad autologousfatgraftinginthetreatmentoffacialscleroderma AT mozafarinikoo autologousfatgraftinginthetreatmentoffacialscleroderma |